Navigation Links
Phase III Study Evaluating Gilead's Viread for the Treatment of,Chronic Hepatitis B Virus Meets Primary Endpoint

he treatment of chronic hepatitis B and the safety and efficacy of Viread have not been established in patients coinfected with HBV and HIV. Severe acute exacerbations of hepatitis B have been reported in patients who have discontinued Viread. Hepatic function should be monitored closely with both clinical and laboratory follow-up for at least several months in patients who are co-infected with HIV and HBV and discontinue Viread. If appropriate, initiation of anti-hepatitis B therapy may be warranted.

Renal impairment, including cases of acute renal failure and Fanconi syndrome, has been reported in association with the use of Viread. It is recommended that creatinine clearance be calculated in all patients prior to initiating therapy with Viread and as clinically appropriate during therapy. Coadministration of Viread and didanosine should be undertaken with caution. Patients should be monitored closely for didanosine-associated adverse events, and didanosine should be discontinued if these occur. Patients on atazanavir and lopinavir/ritonavir plus Viread should be monitored for Viread-associated adverse events, and Viread should be discontinued if these occur. When co-administered with Viread, it is recommended that atazanavir 300 mg be given with ritonavir 100 mg. Atazanavir without ritonavir should not be co-administered with Viread.

Decreases in bone mineral density (BMD) at the lumbar spine and hip have been seen with the use of Viread. The effects of Viread-associated changes in BMD and biochemical markers on long-term bone health and future fracture risk are unknown. Changes in body fat have been observed in patients taking anti-HIV medicines. The cause and long-term health effect of these changes are unknown. Immune Reconstitution Syndrome has been reported in patients treated with combination therapy, including Viread.

The most common adverse events among patients receiving Viread with other antiretroviral agents in a pivotal clinical s
'"/>




Page: 1 2 3 4 5 6 7

Related medicine technology :

1. Data Available From Erbitux Phase III Study in First-Line Treatment of Advanced Lung Cancer
2. Phase 3 Results for Dabigatran Etexilate, an Investigational Oral Anticoagulant, Presented Today at the XXIst Congress of the International Society on Thrombosis and Haemostasis
3. YM BioSciences Announces Secondary Efficacy and Safety Findings in Randomized Phase IIB Aerolef Trial
4. Portola Pharmaceuticals Announces Positive Data from a Phase II Study of its Factor Xa Inhibitor at the XXI Congress of the International Society on Thrombosis and Haemostasis
5. Manhattan Pharmaceuticals Announces Results of Phase 2a Studies for Oral Oleoyl-estrone
6. Actemra (tocilizumab) Third Phase III Study Results Show Significant Improvement in Symptoms of Patients with Rheumatoid Arthritis
7. AVI BioPharma Partner Cook Medical Announces Completion of Patient Enrollment for APPRAISAL Phase II Clinical Trial for Treatment of Cardiovascular Disease
8. NexMed Announces Completion of Patient Enrollment in Two Pivotal Phase 3 Studies for Anti-Fungal Product
9. AM-Pharma Announces Positive Results of Phase IIa Clinical Trial with Alkaline Phosphatase For Ulcerative Colitis
10. Phase III Trial Results Show Superiority of Rivaroxaban over Enoxaparin for the Prevention of Venous Thromboembolism in Patients Undergoing Knee Replacement Surgery
11. Phase III Trial Results Show Superiority of Rivaroxaban over Enoxaparin for the Prevention of Venous Thromboembolism in Patients Undergoing Knee Replacement Surgery
Post Your Comments:
(Date:8/21/2014)... 2014  Decision Resources Group finds that, for ... Brazil and Mexico ... prescribe long-acting beta-agonist (LABA)- and long-acting muscarinic antagonist ... current severe cost/coverage constraints. Therefore, new brands of ... launch in these countries—which will considerably expand the ...
(Date:8/21/2014)... , Aug. 21, 2014  IBM (NYSE: IBM ... ( DESY ), a leading national research center in ... and storage of massive volumes of x-ray data. The ... on IBM software defined technology can handle more than ... and help scientists worldwide gain faster insights into the ...
(Date:8/21/2014)... , Aug. 21, 2014  Seventy-one percent of Americans believe ... is a serious public health and safety issue in ... a survey released today by Repass & Partners, a ... "Americans understand the severity of the prescription medication abuse ... with this very serious health situation facing our country," ...
Breaking Medicine Technology:Novel Fixed-Dose Combinations for COPD in Brazil and Mexico Will Compete With Well-Established Therapies in an Environment Dominated by Aggressive Cost-Control Mechanisms 2Novel Fixed-Dose Combinations for COPD in Brazil and Mexico Will Compete With Well-Established Therapies in an Environment Dominated by Aggressive Cost-Control Mechanisms 3DESY and IBM Develop Big Data Architecture for Science 2DESY and IBM Develop Big Data Architecture for Science 3Consumers Desperate For Measures To Curb Prescription Drug Abuse 2Consumers Desperate For Measures To Curb Prescription Drug Abuse 3
... , , , ... the leader in the development of devices for the percutaneous ... group of patients with the MitraClip((R)) system at the Elisabethinen ... device commercially available in the European Union which provides a ...
... HERNDON, Va., Sept. 8 BHR Pharma, ... global, Phase 3, multi-center pivotal trial ( www.synapse-trial.com ) ... product as a neuroprotective agent for treating severe traumatic brain injury ... will enroll approximately 1,200 patients with severe (Glasgow Coma Scale scores ...
Cached Medicine Technology:MitraClip(R) Therapy Introduced in Austria 2MitraClip(R) Therapy Introduced in Austria 3BHR Pharma Announces Phase 3 SyNAPSe Study of Progesterone as a Neuroprotective Agent for Traumatic Brain Injury 2
(Date:8/21/2014)... -- Not only is eating better and exercising healthy for ... dollars a year, a new study finds. The study, ... at Wake Forest Baptist Medical Center in Winston-Salem, N.C., ... patients. Participants ranged in age from 45 ... "lifestyle change program" focused on diet and exercise, or to ...
(Date:8/21/2014)... Dennis Thompson HealthDay Reporter ... combination of therapy and antidepressants appears to best help ... reports. Four out of five people suffering from ... recovery when treated with cognitive therapy plus antidepressant medication, ... didn,t work much better than drugs alone in helping ...
(Date:8/21/2014)... 2014 A new study published this ... in disability associated with speech problems from 2001-02 to ... 15% increase in disability associated with hearing problems. The ... numbers of children who are experiencing communication disorders, according ... , On a broader level, the new study, ...
(Date:8/21/2014)... Many primary care physicians in rural communities do ... (IPV), according to Penn State medical and public ... such violence have limited resources if they seek ... to help women," said Jennifer S. McCall-Hosenfeld, a ... and public health sciences, Penn State College of ...
(Date:8/21/2014)... New York (PRWEB) August 21, 2014 ... blood thinner caused patients to suffer uncontrollable internal bleeding ... courts, Bernstein Liebhard LLP reports. According to court documents, ... in U.S. District Court, Easter District of New York ... due to a bleeding event that was allegedly caused ...
Breaking Medicine News(10 mins):Health News:Getting Healthier a Big Money-Saver for People With Diabetes 2Health News:Talk Therapy Plus Meds May Be Best for Severe Depression 2Health News:Talk Therapy Plus Meds May Be Best for Severe Depression 3Health News:New Pediatrics Study Reveals Dramatic Increase in Speech Problems in Children Over Past Decade 2Health News:New Pediatrics Study Reveals Dramatic Increase in Speech Problems in Children Over Past Decade 3Health News:Primary care physicians can be critical resource for abused women in rural areas 2Health News:Xarelto Lawsuits Mount With New Filing in New York Federal Court, Bernstein Liebhard LLP Reports 2Health News:Xarelto Lawsuits Mount With New Filing in New York Federal Court, Bernstein Liebhard LLP Reports 3Health News:Xarelto Lawsuits Mount With New Filing in New York Federal Court, Bernstein Liebhard LLP Reports 4
... , , EDEN PRAIRIE, Minn., July 14 ... by Elton John, Billy Crystal, Tony Bennett, and Gladys Knight ... the gift of hearing, raising more than $5 million to ... Hearing Foundation hosted its Ninth Annual "So the World May ...
... change disease from fatal to chronic, researcher says , ... a network of mutated genes and gene processes that, ... type of brain tumor. , "There is not a ... tumors," explained Dr. Markus Bredel, co-author of two related ...
... , , , , ... HLTH ) and its approximately 83% owned subsidiary, WebMD Health Corp. (Nasdaq: ... results for the three months ended June 30, 2009 at approximately 4:00 pm ... at 4:45 pm (ET) on that day to discuss those results. ...
... July 14 Warner Chilcott Limited (Nasdaq: WCRX ) announced ... to the market opening on Friday, August 7, 2009. , ... the Company will host a conference call for all interested parties on ... results. To participate in the call, please dial (888) 208-1812 in the ...
... , CHICAGO, July 14 Earlier today a ... ruling in Zbaraz v. Madigan, a case considering the constitutionality of the ... predecessors -- had long been enjoined from enforcement until today,s ruling. The ... for the ACLU of Illinois : , ...
... ... for surgeon general. , ... Washington, DC (Vocus) June 14, 2009 --    U.S. African Chamber Of Commerce ... physician has been an advocate for universal care, and is expected to have a ...
Cached Medicine News:Health News:Elton John, Billy Crystal, Tony Bennett, and Gladys Knight Help Starkey Hearing Foundation Raise More than $5 Million at Annual Fundraiser 2Health News:Elton John, Billy Crystal, Tony Bennett, and Gladys Knight Help Starkey Hearing Foundation Raise More than $5 Million at Annual Fundraiser 3Health News:Gene Connections Key to Brain Tumor Growth 2Health News:Gene Connections Key to Brain Tumor Growth 3Health News:HLTH and WebMD Announce Second Quarter Earnings Release Date and Conference Call 2Health News:U.S. African Chamber Of Commerce Congratulates U.S. on New Surgeon General, May Improve Health Care for Middle Income Families 2Health News:U.S. African Chamber Of Commerce Congratulates U.S. on New Surgeon General, May Improve Health Care for Middle Income Families 3
... The Nightingale Monitoring System™ expands hospital-grade monitoring ... of subacute care and disease state management. ... ability to encompass a full range of ... patients inside the hospital, to periodic monitoring ...
... FlexNet adds wireless capability to ... This expands the Flexible Monitoring concept ... patient information from anywhere to anywhere. ... ambulatory wireless monitors and hardwired and ...
... Wireless Propaq CS makes ... the Propaq CS even ... with Symbol Technologies, the ... into wireless ethernet Local ...
... The original Welch Allyn ... excellent choice for clinical areas ... Simple and straightforward to use, ... noninvasive blood pressure, and optional ...
Medicine Products: